Bayer's Recovery Gains Steam as Research Deals Offset Legal Uncertainty

Supreme Court rulings bolster Bayer, but $7.25B Roundup settlement awaits approval. Research deals and robust Q1 sales signal turnaround, yet glyphosate sales drop 15% and cash flow remains pressured.

Two pivotal Supreme Court decisions have reshaped the legal landscape for Bayer within the span of six weeks, yet the conglomerate still faces a make-or-break moment in the courtroom. The justices sided with Bayer on the preemption argument in the glyphosate litigation on June 25, handing the company a 7-2 victory, while a separate ruling on May 14 preserved telemedicine access to the abortion pill mifepristone. But the 7.25 billion-dollar Roundup class-action settlement, agreed in February, has yet to receive its final judicial blessing — an essential hearing originally set for early July was postponed, leaving a cloud of uncertainty over the stock.

That stock currently trades at around €48.22, up 1.45% on the day and roughly 73% higher than a year ago. The rally reflects optimism that Bayer is finally turning the page on its legal saga, but the unresolved hearing and a still-pending antidumping petition against Chinese glyphosate imports serve as reminders that the story is far from over.

Research partnerships signal a strategic pivot

Instead of merely waiting for the courts, Bayer has been active on the deal front. On July 17, the group announced a research collaboration with Henry Ford Health, one of only four US healthcare systems selected for the initiative. The partnership aims to accelerate clinical trials in cardiovascular medicine, oncology and women's health by harnessing artificial intelligence and real-world patient data. For investors, the message is clear: Bayer is sharing the hefty cost of drug development through smart partnerships rather than going it alone.

Just two days earlier, the company sealed an exclusive licensing agreement with French seed specialist RAGT to develop hybrid wheat seed varieties for Europe and North America. The technology targets a market launch in the early 2030s, with peak annual revenue potential of up to one billion euros over the ensuing decade. The deal underscores that Bayer's agricultural arm — long overshadowed by the glyphosate controversy — still houses valuable intellectual property that the stock has not fully reflected.

Solid underlying performance, but cash flow remains a drag

Bayer's first-quarter results show a business that is operationally healthy. Group revenues rose 4.1% on a currency- and portfolio-adjusted basis to €13.405 billion, while EBITDA before special items climbed 9.0% to €4.453 billion. The Crop Science division posted higher sales and strong earnings growth, and management expects a partial recovery in glyphosate volumes in Latin America during the second half of the year.

Yet the headline numbers mask structural pressure. Glyphosate-containing product sales slumped 15.1% in the quarter as customers in North America and the EMEA region delayed purchases. The antidumping petition against Chinese glyphosate looks more like a defensive response to pricing pressure than a near-term competitive edge.

More troubling for the balance sheet is the cash flow picture. Free cash flow plunged to minus €2.320 billion, with payments to settle PCB and glyphosate lawsuits alone accounting for a net outflow of €2.002 billion. Net financial debt swelled 9.0% from the end of 2025 to €32.518 billion. These figures temper the enthusiasm around the operational gains.

Analyst confidence holds, but room to run narrows

JPMorgan reaffirmed its "Overweight" rating on July 17, keeping a price target of €50. The bank expects Bayer to reaffirm its full-year guidance when it reports next quarter, with revenue and EBITDA forecasts in line with consensus. The target sits just under €2 above the current share price, suggesting limited upside in the near term unless a catalytic event — such as final approval of the Roundup settlement — unlocks further gains.

Technically, the stock stands 26% above its 200-day moving average, confirming a sustained uptrend. The relative strength index is not yet in overbought territory, and the share price remains about 10% below its 52-week high, leaving some room for a continued rally if the news flow remains supportive.

The hearing that could tip the scales

For all the progress on operations and partnerships, the next major catalyst is the still-unscheduled final hearing on the $7.25 billion Roundup settlement. A smooth confirmation would remove the biggest overhang on Bayer's valuation and reinforce the narrative of a company re-emerging from years of legal defense. A further delay or an unexpected objection could quickly puncture the current mood, given the high volatility that has characterized the stock.

Bayer has come a long way from the days when every headline was about glyphosate. The Supreme Court wins, the partnership deals and the steady operational performance all point in the right direction. But until the settlement hearing is behind it, the recovery story remains hostage to the one variable the company cannot control: the court calendar.